Future pharmacologic management of neuropathic pain

Journal of Orofacial Pain

Volumn 18, Issue 4, 2004, Pages 381-385

  Dray, Andy ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Adenosine triphosphate; Fructalkine; G protein coupled receptors; Ion channels; Kinase

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (N ETHYL N PHENYLAMINO) 1,2 DIMETHYL 6 (METHYLAMINO)PYRIMIDINIUM CHLORIDE; AM 1241; AMITRIPTYLINE; ANALGESIC AGENT; CANNABINOID RECEPTOR AFFECTING AGENT; CHEMOKINE RECEPTOR; CNI 14930; ETANERCEPT; G PROTEIN COUPLED RECEPTOR; GABAPENTIN; HU 308; MEXILETINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUROMED 12; NEUROMED 160; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA CONOTOXIN MVIIA; OPIATE; PD 198306; PURINE RECEPTOR; RALFINAMIDE; SODIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG;

CARDIOTOXICITY; CATALEPSY; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; DIABETIC NEUROPATHY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; ION CHANNEL; MOTOR DYSFUNCTION; NEUROPATHIC PAIN; NEUROTOXICITY; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIDE EFFECT; SODIUM CHANNEL;

ANIMALS; DRUG DESIGN; GANGLIA, SPINAL; HUMANS; ION CHANNELS; MITOGEN-ACTIVATED PROTEIN KINASES; NEUROGLIA; NEUROPEPTIDES; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTEIN KINASE INHIBITORS; RECEPTORS, CHEMOKINE; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PURINERGIC; RECEPTORS, SENSORY;

EID: 8844260446     PISSN: 10646655     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Woolf CJ, Salter MW. Neuronal plasticity: Increasing the gain in pain. Science 2000;288:1765-1769.
2. Bennett G. Neuropathic pain in the orofacial region: Clinical and research challenges. J Orofac Pain 2004;18:281-286.
3. Watkins LR, Maier S. Beyond neurons: Evidence that immune and glial cells contribute to pathological pain states. Physiol Rev 2002;82:981-1011.
4. Moore KA, Kohno T, Karchewski LA, Scholz J, Baba H, Woolf CJ. Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord. J Neurosci 2002;22:6724-6731.
5. Henry J. Future basic science research directions into mechanisms of neuropathic pain. J Orofac Pain 2004;18:306-310.
6. Salter M. Cellular neuroplasticity mechanisms mediating pain persistence. J Orofac Pain 2004;18:318-324.
7. Gracely RH, Lynch SA, Bennett GJ. Painful neuropathy: Altered central processing maintained dynamically by peripheral input. Pain 1992;51:175-194.
8. Coward K, Plumpton C, Facer P, et al. Immunolocalization of SNS/PN3 and NaN/SNS2 sodium channels in human pain states. Pain 2000;85:41-50.
9. Roza C, Laird JMA, Souslova V, Wood JN, Cervero F. The tetrodotoxin-resistant Na+ channel NaV 1.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice. J Physiol 2003;550:921-926.
10. Gold MS, Weinreich D, Kim CS, et al. Redistribution of Na(V)1.8 in uninjured axons enables neuropathic pain. J Neurosci 2003;23:158-166.
11. Hains BC, Klein JP, Saab CY, Craner MJ, Black JA, Waxman SG. Upregulation of sodium channel NaV 1.3 and functional involvement in neuronal hyperexcitability associated with central neuropathic pain after spinal cord injury. J Neurosci 2003;23:8881-8892.
12. Amir R, Liu CN, Kocsis JD, Devor M. Oscillatory mechanism in primary sensory neurons. Brain 2002;125:421-435.
13. Veneroni O, Maj R, Calbresi M, Faravelli L, Fariello RG, Salvati P. Antiallodynic effect of NW-1029, a novel Na(+) channel blocker, in experimental animal models of inflammatory and neuropathic pain. Pain 2003;102:17-25.
14. Luo ZD, Calcutt NA, Higuera ES, et al. Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther 2002;303:1199-1205.
15. Chaplan SR, Guo HQ, Lee DH, et al. Neuronal hyperpolarization-activated pacemaker channels drive neuropathic pain. J Neurosci 2003;23:1169-1178.
16. Malan TP Jr, Ibrahim MM, Lai J, Vanderah TW, Makriyannis A, Porreca F. CB2 cannabinoid receptor agonists: Pain relief without psychoactive effects? Curr Opin Pharmacol 2003;3:1:62-67.
17. Fox A, Kesingland A, Gentry C, et al. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001;92:91-100.
18. Lembo PMC, Grazzini E, Groblewski T, et al. Proenkephalin A gene products activate a new family of sensory neuron-specific GPCRs. Nat Neurosci 2002;5:201-209.
19. Grazzini E, Puma C, Roy M-O, et al. Sensory neuron-specific receptor activation elicits central and peripheral nociceptive effects in rats. Proc Natl Acad Sci U S A 2004;101: 7171-7180.
20. Yu XH, Cao CQ, Mennicken F, et al. Pro-nociceptive effects of neuromedin U in rat. Neuroscience 2003;120: 467-474.
21. Ciruela A, Dixon AK, Bramwell S, Gonzalez MI, Pinnock RD, Lee K. Identification of MEK1 as a novel target for the treatment of neuropathic pain. Br J Pharmacol 2003;138:751-756.
22. Schafers M, Svensson CI, Sommer C, Sorkin LS. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci 2003;23:2517-2521.
23. Watkins LR, Maier SF. Glia: A novel drug discovery target for clinical pain. Nat Rev Drug Discov 2003;2:973-985.
24. Chassell IP, Hatcher JP, Davey PT, et al. Disruption of the P2x7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Nature. In press.
25. 4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 2003;424:778-783.
26. Abbadie C, Lindia JA, Cumiskey AM, et al. Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci USA 2003;100: 7947-7952.